BRISTOL-MYERS SQUIBB PHARMACEUTICALS LIMITED
Company Information
- Company Number
- 02487574
- Registered Address
- Arc Uxbridge Sanderson Road, New Denham, Denham, Buckinghamshire, United Kingdom, UB8 1DH
- Status
- Active
- Employee Count
- 463
- Turnover
- £563,121,000
- EBITDA
- £18,645,000
Additional Details
- Website
- https://bmsmedinfo.co.uk/
- Company Type
- Private limited Company
- Incorporated On
- 2 April 1990
- Nature of Business
- 21100 - Manufacture of basic pharmaceutical products
- Industries
- Life Sciences And Medical Technology
- Region
- South East
Time to Pay
Payment Timeline
Payment Features
Payment Score History
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jan 2025 - 30 Jun 2025 | 28 Jul 2025 | 50 | 35% | 34% | 31% | 22% |
| 01 Jul 2023 - 31 Dec 2023 | 30 Jan 2024 | 42 | 41% | 37% | 22% | 27% |
| 01 Jan 2022 - 30 Jun 2022 | 15 Jul 2022 | 40 | 45% | 34% | 21% | 27% |
| 01 Jan 2021 - 30 Jun 2021 | 29 Jul 2021 | 46 | 41% | 26% | 33% | 28% |
| 01 Jul 2020 - 31 Dec 2020 | 29 Jan 2021 | 41 | 44% | 29% | 27% | 31% |
| 01 Jan 2019 - 30 Jun 2019 | 19 Jul 2019 | 41 | 52% | 18% | 30% | 40% |
| 01 Jul 2018 - 31 Dec 2018 | 25 Jan 2019 | 41 | 48% | 28% | 24% | 34% |
Payment Time Trends
Payment Distribution Trends
Invoice Payment Practices
This information is as reported by the business, and responses are in their own words.
Payment Terms
Standard payment terms
The preferred BMS terms for 3rd party vendors are default to 90 days. Payment terms are outlined in contracts with suppliers. Where a contract is not negotiated, the payment terms will be clearly stated on the Purchase Orders (POs) sent to suppliers. Any changes to the payment terms would require a contract amendment. For Health Care Professionals the standard payment terms are immediate, therefore meeting these terms are difficult to achieve when we consider time to send the invoice, process, approve and release for payment, currently 72% of the above reported late payments are due to Immediate payment terms. Intercompany transactions may also negatively impact the On-time payment percentage due to the Intercompany monthly netting schedule (a further 10% of late payments).
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
90
Dispute Resolution Process
BMS has a dedicated Accounts Payable helpdesk in the event of a dispute with a supplier that offers them support through to query resolution. This query can be raised via email at frontoffice-UK@bms.com. If needed the query is then forwarded to the BMS contact (contract monitor or requisitioner) for further investigation. During the COVID pandemic, suppliers are advised to use email to reach the team, they have also been encouraged to submit paper invoices by email, as there had been some slight delays with paper invoice processing due to site access restrictions for collection/scanning into the processing pipeline, best efforts have been made to minimise the impact to payments.
Other Payment Information
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Company Summary
Bristol-Myers Squibb Pharmaceuticals Limited is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines for patients with serious diseases. The company is committed to improving patient outcomes and advancing medical research through their sustainable practices.
One of their major sustainability programs is the "BioPharma sustainability strategy" which aims to reduce the company's environmental impact, promote access to healthcare, and support the well-being of their employees. This program includes initiatives such as reducing carbon emissions, increasing energy efficiency, and promoting responsible waste management.
Bristol-Myers Squibb offers a wide range of products and services in various therapeutic areas including oncology, cardiovascular disease, and immunology. Their portfolio includes well-known brands such as Opdivo, Eliquis, and Orencia. They also have a strong pipeline of potential new treatments for diseases with high unmet medical needs.
The key people at Bristol-Myers Squibb Pharmaceuticals Limited include CEO Giovanni Caforio, Chief Scientific Officer Thomas Lynch, and Chief Financial Officer Charles Bancroft.
Contact information for Bristol-Myers Squibb Pharmaceuticals Limited can be found on their website at www.bms.com. Their registered office address is 5 New Street Square, London, EC4A 3TW, United Kingdom.
